MONTE ROSA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MODEFIRE-1, A PHASE 2 STUDY OF MRT-2359 IN COMBINATION WITH APALUTAMIDE IN PATIENTS WITH AR MUTATION-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Reuters · 2d ago

Please log in to view news